{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:02:37Z","timestamp":1790388157464,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-024-10039-2","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T04:02:44Z","timestamp":1729483364000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Incidence of serious respiratory tract infections and associated characteristics in a population exposed to immunosuppressive therapies: a register-based population study"],"prefix":"10.1186","volume":"24","author":[{"given":"Cindy","family":"Etienne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Maria","family":"Vilcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Finet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Chawki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Blanchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Steichen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hanslik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"key":"10039_CR1","doi-asserted-by":"crossref","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2023;ard-2022-223764.","DOI":"10.1136\/ard-2022-223764"},{"issue":"1","key":"10039_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10039_CR3","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10039_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","volume":"79","author":"B Hellmich","year":"2020","unstructured":"Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19\u201330.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10039_CR5","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736\u201345.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10039_CR6","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/apt.13671","volume":"44","author":"N Narula","year":"2016","unstructured":"Narula N, Kainz S, Petritsch W, Haas T, Feichtenschlager T, Novacek G, et al. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-\u03b1 na\u00efve Crohn\u2019s disease. Aliment Pharmacol Ther. 2016;44(2):170\u201380.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10039_CR7","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/jdv.13354","volume":"29","author":"A Nast","year":"2015","unstructured":"Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris\u2013update 2015\u2013Short version\u2013EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol JEADV. 2015;29(12):2277\u201394.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"10039_CR8","doi-asserted-by":"crossref","unstructured":"Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;(2):CD008794.","DOI":"10.1002\/14651858.CD008794"},{"issue":"6","key":"10039_CR9","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1136\/annrheumdis-2012-201338","volume":"72","author":"SAA van Dartel","year":"2013","unstructured":"van Dartel SAA, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch rheumatoid arthritis monitoring (DREAM) registry. Ann Rheum Dis. 2013;72(6):895\u2013900.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10039_CR10","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/acr.21666","volume":"64","author":"R Sakai","year":"2012","unstructured":"Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H, et al. Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res. 2012;64(8):1125\u201334.","journal-title":"Arthritis Care Res"},{"issue":"7","key":"10039_CR11","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1093\/rheumatology\/ker146","volume":"50","author":"JB Galloway","year":"2011","unstructured":"Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Watson KD, Lunt M, et al. The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatol Oxf Engl. 2011;50(7):1341\u20132.","journal-title":"Rheumatol Oxf Engl"},{"issue":"1","key":"10039_CR12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"JB Galloway","year":"2011","unstructured":"Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatol Oxf Engl. 2011;50(1):124\u201331.","journal-title":"Rheumatol Oxf Engl"},{"issue":"5","key":"10039_CR13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.semarthrit.2008.10.002","volume":"39","author":"DE Furst","year":"2010","unstructured":"Furst DE. The risk of infections with Biologic therapies for Rheumatoid Arthritis. Semin Arthritis Rheum. 2010;39(5):327\u201346.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10039_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10067-021-05880-8","volume":"41","author":"M Rivera","year":"2022","unstructured":"Rivera M, Villafranca A, Khamooshi P, Reyes V, Sanchez J, Manadan A. Reasons for hospitalization and in-hospital mortality for anti-neutrophil cytoplasmic antibody vasculitides: analysis of the National Inpatient Sample. Clin Rheumatol. 2022;41(1):159\u201366.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10039_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/art.39399","volume":"68","author":"H Yun","year":"2016","unstructured":"Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, et al. Comparative risk of hospitalized infection Associated with Biologic agents in Rheumatoid Arthritis patients enrolled in Medicare. Arthritis Rheumatol Hoboken NJ. 2016;68(1):56\u201366.","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"6","key":"10039_CR16","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/art.39070","volume":"67","author":"CH Feldman","year":"2015","unstructured":"Feldman CH, Hiraki LT, Winkelmayer WC, Marty FM, Franklin JM, Kim SC, et al. Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol Hoboken NJ. 2015;67(6):1577\u201385.","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10039_CR17","doi-asserted-by":"publisher","first-page":"1110548","DOI":"10.3389\/fmed.2023.1110548","volume":"10","author":"A Vassilopoulos","year":"2023","unstructured":"Vassilopoulos A, Vassilopoulos S, Kalligeros M, Shehadeh F, Mylonakis E. Incidence of serious infections in patients with ANCA-associated vasculitis receiving immunosuppressive therapy: a systematic review and meta-analysis. Front Med. 2023;10:1110548.","journal-title":"Front Med"},{"issue":"7","key":"10039_CR18","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1093\/ecco-jcc\/jjz013","volume":"13","author":"Y Zabana","year":"2019","unstructured":"Zabana Y, Rodr\u00edguez L, Lobat\u00f3n T, Gordillo J, Montserrat A, Mena R, et al. Relevant infections in inflammatory bowel Disease, and their relationship with immunosuppressive therapy and their effects on Disease Mortality. J Crohns Colitis. 2019;13(7):828\u201337.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"10039_CR19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1086\/431587","volume":"41","author":"LMaJ Muller","year":"2005","unstructured":"Muller LMaJ, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AIM, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis off Publ Infect Dis Soc Am. 2005;41(3):281\u20138.","journal-title":"Clin Infect Dis off Publ Infect Dis Soc Am"},{"key":"10039_CR20","unstructured":"HCSP. Infections \u00e0 pneumocoque: recommandations vaccinales pour les adultes [Internet]. Rapport de l\u2019HCSP. Paris: Haut Conseil de la Sant\u00e9 Publique; 2017 Mar [cited 2022 Sep 18]. https:\/\/www.hcsp.fr\/explore.cgi\/avisrapportsdomaine?clefr=614"},{"issue":"6","key":"10039_CR21","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1136\/annrheumdis-2015-207362","volume":"75","author":"JH Salmon","year":"2016","unstructured":"Salmon JH, Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, et al. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry. Ann Rheum Dis. 2016;75(6):1108\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10039_CR22","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1093\/rheumatology\/kex238","volume":"56","author":"J Morel","year":"2017","unstructured":"Morel J, Constantin A, Baron G, Dernis E, Flipo RM, Rist S, et al. Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE. Rheumatol Oxf Engl. 2017;56(10):1746\u201354.","journal-title":"Rheumatol Oxf Engl"},{"issue":"10","key":"10039_CR23","doi-asserted-by":"publisher","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","volume":"12","author":"EI Benchimol","year":"2015","unstructured":"Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The REporting of studies conducted using Observational routinely-collected health data (RECORD) Statement. PLOS Med. 2015;12(10):e1001885.","journal-title":"PLOS Med"},{"issue":"4","key":"10039_CR24","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.respe.2010.04.005","volume":"58","author":"P Tuppin","year":"2010","unstructured":"Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merli\u00e8re Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique. 2010;58(4):286\u201390.","journal-title":"Rev Epidemiol Sante Publique"},{"issue":"3","key":"10039_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3917\/pos.403.0213","volume":"40","author":"L De Roquefeuil","year":"2009","unstructured":"De Roquefeuil L, Studer A, Neumann A, Merli\u00e8re Y. L\u2019\u00e9chantillon g\u00e9n\u00e9raliste de b\u00e9n\u00e9ficiaires: repr\u00e9sentativit\u00e9, port\u00e9e et limites. Prat Organ Soins. 2009;40(3):213\u201323.","journal-title":"Prat Organ Soins"},{"issue":"8","key":"10039_CR26","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/pds.4233","volume":"26","author":"J Bezin","year":"2017","unstructured":"Bezin J, Duong M, Lassalle R, Droz C, Pariente A, Blin P, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954\u201362.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10039_CR27","doi-asserted-by":"publisher","first-page":"R645","DOI":"10.1186\/cc3821","volume":"9","author":"JR Le Gall","year":"2005","unstructured":"Le Gall JR, Neumann A, Hemery F, Bleriot JP, Fulgencio JP, Garrigues B, et al. Mortality prediction using SAPS II: an update for French intensive care units. Crit Care Lond Engl. 2005;9(6):R645\u2013652.","journal-title":"Crit Care Lond Engl"},{"issue":"9","key":"10039_CR28","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/MLR.0000000000001745","volume":"60","author":"A Rachas","year":"2022","unstructured":"Rachas A, Gastaldi-M\u00e9nager C, Denis P, Barth\u00e9l\u00e9my P, Constantinou P, Drouin J, et al. The Economic Burden of Disease in France from the National Health Insurance Perspective: the Healthcare expenditures and conditions Mapping used to prepare the French Social Security Funding Act and the Public Health Act. Med Care. 2022;60(9):655.","journal-title":"Med Care"},{"key":"10039_CR29","unstructured":"Cancer Incidence in. Five Continents [Internet]. [cited 2023 Jun 16]. https:\/\/link.springer.com\/book\/9783540034759"},{"issue":"1","key":"10039_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/thx.2009.129502","volume":"67","author":"T Welte","year":"2012","unstructured":"Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67(1):71\u20139.","journal-title":"Thorax"},{"key":"10039_CR31","doi-asserted-by":"crossref","unstructured":"Partouche H, Lepoutre A, Vaure CB du, Poisson T, Toubiana L, Gilberg S. Incidence of all-cause adult community-acquired pneumonia in primary care settings in France. Med Mal Infect. 2018;48(6):389\u201395.","DOI":"10.1016\/j.medmal.2018.02.012"},{"issue":"2","key":"10039_CR32","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.chest.2017.09.041","volume":"153","author":"BH Hayes","year":"2018","unstructured":"Hayes BH, Haberling DL, Kennedy JL, Varma JK, Fry AM, Vora NM. Burden of Pneumonia-Associated hospitalizations. Chest. 2018;153(2):427\u201337.","journal-title":"Chest"},{"issue":"10","key":"10039_CR33","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1080\/14787210.2019.1671823","volume":"17","author":"C Cill\u00f3niz","year":"2019","unstructured":"Cill\u00f3niz C, Domined\u00f2 C, \u00c1lvarez-Mart\u00ednez MJ, Moreno A, Garc\u00eda F, Torres A, et al. Pneumocystis pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients. Expert Rev Anti Infect Ther. 2019;17(10):787\u2013801.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"12","key":"10039_CR34","doi-asserted-by":"publisher","first-page":"e124211","DOI":"10.1016\/j.amjmed.2014.07.010","volume":"127","author":"P Fillatre","year":"2014","unstructured":"Fillatre P, Decaux O, Jouneau S, Revest M, Gacouin A, Robert-Gangneux F, et al. Incidence of Pneumocystis Jiroveci pneumonia among groups at risk in HIV-negative patients. Am J Med. 2014;127(12):e124211\u201317.","journal-title":"Am J Med"},{"issue":"12","key":"10039_CR35","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1136\/thx.2008.109785","volume":"64","author":"S Ewig","year":"2009","unstructured":"Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H, et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax. 2009;64(12):1062\u20139.","journal-title":"Thorax"},{"issue":"8","key":"10039_CR36","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/art.23913","volume":"59","author":"D Lacaille","year":"2008","unstructured":"Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59(8):1074\u201381.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10039_CR37","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/art.21568","volume":"54","author":"F Wolfe","year":"2006","unstructured":"Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti\u2013tumor necrosis factor therapy. Arthritis Rheum. 2006;54(2):628\u201334.","journal-title":"Arthritis Rheum"},{"issue":"9990","key":"10039_CR38","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","volume":"386","author":"JA Singh","year":"2015","unstructured":"Singh JA, Cameron C, Noorbaloochi S, Cullis T, Tucker M, Christensen R, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet Lond Engl. 2015;386(9990):258\u201365.","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10039_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.respe.2011.07.005","volume":"60","author":"L Grammatico-Guillon","year":"2012","unstructured":"Grammatico-Guillon L, Thiercelin N, Mariani S, Lecuyer AI, Goudeau A, Bernard L, et al. [Study of hospitalizations for pneumococcal pneumoniae in Centre region, 2004\u20132008]. Rev Epidemiol Sante Publique. 2012;60(1):1\u20138.","journal-title":"Rev Epidemiol Sante Publique"},{"issue":"1","key":"10039_CR40","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1186\/s12879-021-06669-5","volume":"21","author":"E Blanc","year":"2021","unstructured":"Blanc E, Chaize G, Fievez S, F\u00e9ger C, Herquelot E, Vainchtock A, et al. The impact of comorbidities and their stacking on short- and long-term prognosis of patients over 50 with community-acquired pneumonia. BMC Infect Dis. 2021;21(1):949.","journal-title":"BMC Infect Dis"},{"key":"10039_CR41","doi-asserted-by":"publisher","first-page":"105635","DOI":"10.1016\/j.jcv.2023.105635","volume":"171","author":"P Loubet","year":"2024","unstructured":"Loubet P, Fernandes J, de Pouvourville G, Sosnowiez K, Elong A, Guilmet C, et al. Respiratory syncytial virus-related hospital stays in adults in France from 2012 to 2021: a national hospital database study. J Clin Virol off Publ Pan Am Soc Clin Virol. 2024;171:105635.","journal-title":"J Clin Virol off Publ Pan Am Soc Clin Virol"},{"issue":"4","key":"10039_CR42","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/irv.12962","volume":"16","author":"M Lemaitre","year":"2022","unstructured":"Lemaitre M, Fouad F, Carrat F, Cr\u00e9pey P, Gaillat J, Gavazzi G, et al. Estimating the burden of influenza-related and associated hospitalizations and deaths in France: an eight-season data study, 2010\u20132018. Influenza Other Respir Viruses. 2022;16(4):717\u201325.","journal-title":"Influenza Other Respir Viruses"},{"issue":"3","key":"10039_CR43","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/irv.12719","volume":"14","author":"M Pivette","year":"2020","unstructured":"Pivette M, Nicolay N, de Lauzun V, Hubert B. Characteristics of hospitalizations with an influenza diagnosis, France, 2012\u20132013 to 2016\u20132017 influenza seasons. Influenza Other Respir Viruses. 2020;14(3):340\u20138.","journal-title":"Influenza Other Respir Viruses"},{"issue":"3","key":"10039_CR44","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.resinv.2024.02.015","volume":"62","author":"SI Ohmura","year":"2024","unstructured":"Ohmura SI, Matsui H, Miyamoto T, Shichi D, Masui T, Ichijo K, et al. Comparison of the outcomes of Pneumocystis Jirovecii pneumonia in rheumatoid arthritis patients treated with and without biologics. Respir Investig. 2024;62(3):377\u201383.","journal-title":"Respir Investig"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10039-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-10039-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10039-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T16:02:18Z","timestamp":1729526538000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-10039-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["10039"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-10039-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"assertion":[{"value":"26 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The French Commission on Information Technology and Liberties (CNIL) approved the French national health data system (SNDS), including the EGB database used in this study; informed consent is waived for the use of these anonymized secondary data, as mentioned in the Social Security Code, Article L161\u201328\u2009\u2212\u20091. As per the decree no. 2016\u2009\u2212\u20091871 of December 26, the French National Institute for Health and Medical Research (INSERM) has a permanent right to access the EGB database. Thus, no additional approval from an ethical committee or a national commission for the protection of individual data was required. The research protocol of the current study is compliant with the internal control process set up by the Inserm SNDS Service Center, in conjunction with the establishment\u2019s data protection delegate (DPO); Internal compliance approval was granted on 25\/07\/2022. Access to the EGB database was possible only through a secure connection to a specific server. Data access and management were conducted using the software SAS Enterprise Guide version 7.15 (Copyright \u00a9 2006\u20132010, SAS Institute Inc., Cary, NC, USA). Access to the SNDS database is granted to Inserm research units by French legislation (article R1461-13 of Code de la Sant\u00e9 Publique). Under this legal framework, studies approved by Inserm\u2019s data committee using data solely from French medico-administrative databases (SNDS) do not require separate ethics committee authorization. The SNDS does not contain any data that is directly identified. The application of all measures to preserve data confidentiality, integrity, and traceability of access and other processing, as described by the law (article R1461-1 of Code de la Sant\u00e9 Publique), are guaranteed by Inserm.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"1184"}}